Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia

• Published in: Scientific reports Vol. 13; no. 1; pp. 18199 - 10
• Main Authors: Volz, Christian, Zerjatke, Thomas, Gottschalk, Andrea, Semper, Sabine, Suttorp, Meinolf, Glauche, Ingmar, Krumbholz, Manuela, Metzler, Markus
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.10.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/699/1541/1990; 692/700/1720/3187; Cell number; Chronic myeloid leukemia; Fusion protein; Humanities and Social Sciences; Kinases; Leukemia; multidisciplinary; Myeloid leukemia; Patients; Pediatrics; Protein-tyrosine kinase; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-45364-0

Response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is monitored by quantification of BCR::ABL1 transcript levels. Milestones for assessing optimal treatment response have been defined in adult CML patients and are applied to children and adolescents although it is questionable whether transferability to pediatric patients is appropriate regarding genetic and clinical differences. Therefore, we analyzed the molecular response kinetics to TKI therapy in 129 pediatric CML patients and investigated whether response assessment based on continuous references can support an early individual therapy adjustment. We applied a moving quantiles approach to establish a high-resolution response target curve and contrasted the median responses in all patients with the median of the ideal target curve obtained from a subgroup of optimal responders. The high-resolution response target curve of the optimal responder group presents a valuable tool for continuous therapy monitoring of individual pediatric CML patients in addition to the fixed milestones. By further comparing BCR::ABL1 transcript levels with BCR::ABL1 fusion gene copy numbers, it is also possible to model the differential dynamics of BCR::ABL1 expression and cell number under therapy. The developed methodology can be transferred to other biomarkers for continuous therapy monitoring.